Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression‐free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RM...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Stewart, A. Keith, Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David, Mihaylov, Georgi G., Goranova‐Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej, San‐Miguel, Jesus, Ludwig, Heinz, Palumbo, Antonio, Obreja, Mihaela, Aggarwal, Sanjay, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412871/
https://www.ncbi.nlm.nih.gov/pubmed/28211560
http://dx.doi.org/10.1111/bjh.14549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412871/
https://www.ncbi.nlm.nih.gov/pubmed/28211560
http://dx.doi.org/10.1111/bjh.14549

Ejemplares similares